Enanta Pharmaceuticals Future Growth
Future criteria checks 0/6
Enanta Pharmaceuticals is forecast to grow earnings and revenue by 7.8% and 1.6% per annum respectively. EPS is expected to grow by 15.1% per annum. Return on equity is forecast to be -62.9% in 3 years.
Key information
7.8%
Earnings growth rate
15.1%
EPS growth rate
Biotechs earnings growth | 31.1% |
Revenue growth rate | 1.6% |
Future return on equity | -62.9% |
Analyst coverage | Good |
Last updated | 09 Feb 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
9/30/2026 | 73 | -118 | -190 | N/A | 6 |
9/30/2025 | 73 | -116 | -125 | -111 | 8 |
9/30/2024 | 69 | -110 | -123 | -92 | 8 |
12/31/2023 | 74 | -138 | -99 | -93 | N/A |
9/30/2023 | 79 | -134 | -112 | -103 | N/A |
6/30/2023 | 81 | -132 | -106 | -97 | N/A |
3/31/2023 | 81 | -125 | -102 | -95 | N/A |
12/31/2022 | 82 | -121 | -112 | -107 | N/A |
9/30/2022 | 86 | -122 | -87 | -85 | N/A |
6/30/2022 | 89 | -120 | -91 | -90 | N/A |
3/31/2022 | 92 | -112 | -91 | -90 | N/A |
12/31/2021 | 93 | -101 | -69 | -68 | N/A |
9/30/2021 | 97 | -79 | -71 | -70 | N/A |
6/30/2021 | 97 | -84 | -65 | -64 | N/A |
3/31/2021 | 94 | -74 | -40 | -39 | N/A |
12/31/2020 | 102 | -58 | -21 | -20 | N/A |
9/30/2020 | 122 | -36 | 6 | 7 | N/A |
6/30/2020 | 150 | 2 | 30 | 31 | N/A |
3/31/2020 | 176 | 24 | 35 | 38 | N/A |
12/31/2019 | 188 | 34 | 48 | 54 | N/A |
9/30/2019 | 205 | 46 | 66 | 71 | N/A |
6/30/2019 | 221 | 65 | 85 | 91 | N/A |
3/31/2019 | 234 | 78 | 88 | 93 | N/A |
12/31/2018 | 238 | 86 | 52 | 55 | N/A |
9/30/2018 | 207 | 72 | 26 | 29 | N/A |
6/30/2018 | 215 | 81 | 56 | 58 | N/A |
3/31/2018 | 166 | 52 | 47 | 49 | N/A |
12/31/2017 | 131 | 34 | 52 | 54 | N/A |
9/30/2017 | 103 | 18 | N/A | 53 | N/A |
6/30/2017 | 40 | -21 | N/A | -7 | N/A |
3/31/2017 | 46 | -13 | N/A | -4 | N/A |
12/31/2016 | 50 | -10 | N/A | 9 | N/A |
9/30/2016 | 88 | 22 | N/A | 36 | N/A |
6/30/2016 | 90 | 29 | N/A | 36 | N/A |
3/31/2016 | 87 | 33 | N/A | 23 | N/A |
12/31/2015 | 132 | 63 | N/A | 112 | N/A |
9/30/2015 | 161 | 79 | N/A | 77 | N/A |
6/30/2015 | 149 | 68 | N/A | 74 | N/A |
3/31/2015 | 180 | 116 | N/A | 123 | N/A |
12/31/2014 | 124 | 82 | N/A | 20 | N/A |
9/30/2014 | 48 | 34 | N/A | 20 | N/A |
6/30/2014 | 46 | 35 | N/A | 23 | N/A |
3/31/2014 | 6 | -19 | N/A | -18 | N/A |
12/31/2013 | 5 | -19 | N/A | -4 | N/A |
9/30/2013 | 32 | -7 | N/A | 11 | N/A |
6/30/2013 | 33 | -3 | N/A | 11 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 9EP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 9EP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 9EP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 9EP's revenue (1.6% per year) is forecast to grow slower than the German market (5.5% per year).
High Growth Revenue: 9EP's revenue (1.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 9EP is forecast to be unprofitable in 3 years.